Send to

Choose Destination
Saudi J Biol Sci. 2018 Jul;25(5):909-916. doi: 10.1016/j.sjbs.2018.01.011. Epub 2018 Jan 31.

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment.

Author information

Department of Medical Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Department of Maternal and Child Health, School of Public Health, Peking University, Beijing 100191, China.
Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC 20057, USA.
Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin 150081, China.


The goal of this study was to assess the antitumor efficacy and safety of lobaplatin-based regimens as the second line of treatment in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes, compared with that of cisplatin-based regimens. During August 2012 to April 2015, 87 patients who received lobaplatin-based regimens or cisplatin-based regimens were included. Medical records of the patients noted that lobaplatin (30 mg/m2) or cisplatin (25 mg/m2), combined with another chemotherapeutic agent such as Gemcitabine (1000 mg/m2) or Vinorelbine (25 mg/m2), was intravenously given to the patients on a basis of twenty-one days as one treatment cycle. All the patients were followed until August 2017. The endpoint of this study was progression-free survival (PFS), overall survival (OS), and estimated objective response rate (RR). Safety and drug tolerability data were also obtained. Lobaplatin-based regimens prolonged PFS compared to cisplatin-based regimens (median 13.2 vs 4.7 months, hazard ratio = 0.37, 95% confidence intervals: 0.21-0.67, P = .0007), while OS was not significantly different between the two groups (hazard ratio = 0.72, 95% confidence intervals: 0.40-1.30, P = .2767), as was objective RR (37.8% vs 33.4%, x2 = 0.19, P = .6653). Nausea/vomiting and renal injury were more frequent with cisplatin-based regimens. Our results show that lobaplatin-based regimens are superior to cisplatin in terms of efficacy and are better tolerated.


Breast cancer; Cisplatin; Eastern Cooperative Oncology Group, ECOG; Lobaplatin; Metastatic; National Cancer Institute Common Toxicity Criteria for Adverse Events, NCI-CTCAE; Resistant; Response Evaluation Criteria in Solid Tumors, RECIST; cisplatin and gemcitabine, GP; cisplatin and vinorelbine, NP; complete response, CR; confidence interval, CI; estrogen receptor, ER; granulocyte-colony stimulating factor, G-CSF; hazard ratio, HR; human epidermal growth factor receptor 2, HER-2; lobaplatin and gemcitabine, GL; lobaplatin and vinorelbine, NL; lymph nodes, LN; metastatic breast cancer, MBC; non-small-cell lung cancer, NSCLC; overall survival, OS; partial response, PR; performance scale, PS; platinum-based compounds, PBCs; progesterone receptor, PR; progression-free survival, PFS; progressive disease, PD; response rate, RR; stable disease, SD; standard error, SE; time to progression, TTP; triple negative breast cancer, TNBC

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center